Kornimate/medical-research-clean huggingface dataset:
long term effect of splenectomy on metabolism

Conditions: Trauma Splenic

Summary: metabolic status of patients who had gone through trauma splenectomy between july 2008 and july 2013 were compared to patients who had gone through bowel resection due to obstruction in the same period of time. all patients were followed up for 5-10 years.

a list was made of patients who had gone through trauma splenectomy or bowel resection due to bowel obstruction in our center between july 2008 and july 2013. patients were divided into two groups: trauma splenectomy (exposed group) and bowel resection (unexposed group). all patients were followed up for 5-10 years. of the 243 splenectomized patients, 90 patients who met our study criteria were willing to participate. of 152 patients with bowel resection, 64 were willing to participate. records of patients at the time of surgery were retrieved from hospital archive of patients' records. patients were invited to an office meeting for assessment of blood pressure, bmi and a general physical examination and history taking. an appointment was made for drawing blood samples for measurement of lipid profile, hb a1c and fasting blood sugar. exclusion criteria: 1. disturbed lipid profile at the time of surgery, 2. disturbed blood glucose levels at the time of surgery, 3. history of high blood pressure prior to surgery, 4. use of any hyperglycemogenic agent during the follow up period, 5. bmi\>= 25 at the time of surgery, 6. history of diseases potentially affecting blood glucose, e.g. hyperthyroidism, cushing syndrome, 7. accidental pancreatic damage during surgery, 8. resection of \>10 cm of small bowel and 9. history of malignancy or radiotherapy (criteria 8 and 9 were specific to unexposed group).

Eligibility criteria:
inclusion criteria: * trauma splenectomy or bowel resection due to obstruction between july 2008 and july 2013 exclusion criteria: * disturbed lipid profile at the time of surgery * disturbed blood glucose at the time of surgery * history of high blood pressure at the time of surgery * use of any hyperglcemogenic agent during the follow up * bmi\>= 25 at the time of surgery * history of diseases that can affect blood glucose levels * accidental pancreatic damage during surgery * resection of \> 10 cm of small bowel (for bowel resection group) * history of malignancy or radiotherapy (for bowel resection group)

Keywords: splenectomy metabolism diabetes stem cells trauma surgery
a pilot study of ultrasound-guided vacuum-assisted excision of breast cancers

Conditions: Breast Cancer

Summary: this study is looking into whether the procedure called vacuum assisted excision (vae) is a safe method for the removal of small and medium sized invasive breast cancers in patients who are unfit or have refused to have surgery to remove cancer. recruitment target: 20


Eligibility criteria:
inclusion criteria: * the patient is aged 18 years or older. * diagnosis on core needle biopsy of invasive cancer of the breast * unifocal invasive tumour on imaging (hormone receptor positive or negative) * t1 or t2 primary or locally recurrent tumour measuring ≤25mm on imaging, excluding any adjacent ductal carcinoma in situ (largest of the measurements on mammography (including digital breast tomosynthesis if performed) and ultrasound) * the tumour is clearly visible on ultrasound * vacuum-assisted excision of the entire ultrasonically visible tumour is deemed to be technically feasible * the patient is considered to be at high risk of complications or death from a general anaesthetic and therefore surgery under general anaesthesia is not considered appropriate. this must be confirmed by agreement by two named consultant breast surgeons, a multidisciplinary team meeting (including at least one consultant breast surgeon) or by formal anaesthetic assessment. unsuitability for surgery under local anaesthetic must be confirmed by a consultant breast surgeon. * or - the patient refuses to undergo surgery. this must be confirmed by a consultant surgeon and breast care nurse following full discussion of the treatment options. * or - the patient is considered unlikely to benefit from surgical removal of the cancer by virtue of known metastatic disease or other life-shortening condition. this must be confirmed by discussion in a multidisciplinary team meeting which includes an oncologist. * the patient has given written informed consent for the study women who are already on primary endocrine therapy for a breast cancer and meet the inclusion criteria will also be eligible. exclusion criteria: * the patient is on anticoagulants or has a known clotting disorder * pregnancy or lactation * allergy to local anaesthetic
polymorphonuclear cells' sensitivity to aggregatibacter actinomycetemcomitans bacteria in patients with aggressive periodontitis

Conditions: Periodontal Disease

Summary: aggressive periodontitis is an inflammatory disease which damage the teeth supporting structures mostly in young patients. and has genetic basis. a specific bacteria: aggregatibacter actinomycetemcomitans (aa) is associated with this disease, and found to damage leukocytes by using a specific leukotoxin. in the research the investigators are aiming to find molecular and immunological basis to aggressive periodontitis.


Eligibility criteria:
inclusion criteria: * patients in periodontal department * healthy * diagnosed with chronic/aggressive periodontal disease * interested in participating the research exclusion criteria: * diagnosed with diabetes, heart disease, immunosuppression, thrombocytopenia, clotting enzyme deficiency. * using alcohol, or drugs * pregnancy
methylphenidate treatment of cancer-related fatigue

Conditions: Cancer-related Fatigue

Summary: the purpose of this randomized controlled clinical trial is to investigate the efficacy and safety of methylphenidate in patients with fatigue caused by cancer.


Eligibility criteria:
inclusion criteria: * history of cancer * mfi \>40 * karnofsky index \>=70 * outpatient * patient are able to give informed consent exclusion criteria: * treatment with psychostimulants in the past two weeks before screening * active tumor disease * depression (hads \>10) * cachexia (bmi \<18kg/m2) * clinically relevant kidney disorders * clinically relevant liver disorder * pathological ecg-finding * high blood pressure * occlusive arterial disease * angina pectoris * cardiac arrhythmias * chd * post heart-attack status * post stroke status * known elevated intra-ocular pressure * known enlarged prostates * latent and manifest hyperthyreosis * alcohol, medication or drug dependency in the past six months or manifest drug abuse * participation in a clinical study within the past 30 days * participation in this study at an earlier point in time * simultaneous participation in another clinical trial * women of child-bearing age without adequate contraception (contraceptives, intrauterine device , no sexual intercourse) * pregnancy (positive pregnancy test) or lactation period

Keywords: fatigue, cancer, methylphenidate,
osia cpt code study

Conditions: Conductive Hearing Loss; Mixed Hearing Loss

Summary: to evaluate the clinical efficacy of the osia 2 system in patients with conductive or mixed conductive hearing loss in a us cohort.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent. * proficient in english. * hearing loss etiology of conductive or mixed conductive loss. * bone conduction pta (.5, 1, 2, and 3 khz) better than or equal to 55 db hl in the treatment ear. * aged 18 years and older. exclusion criteria: * unwilling to wear the treatment device or comply with the surgical and rehabilitation requirements of the study. * unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator. * medical, audiological or psychological conditions, as judged by the investigator that might contraindicate participation in the clinical investigation. * investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling. * cochlear employees or contractors engaged by cochlear for the purposes of this investigation. * currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device. * prior experience with a surgical bone conduction treatment option * insufficient bone quality to support the bi300 implant as determined by the surgeon

Keywords: conductive hearing loss mixed hearing loss
trial to evaluate anticoagulation therapy in hemodialysis patients with atrial fibrillation

Conditions: Atrial Fibrillation; End Stage Renal Disease

Summary: this is a prospective, randomized, open-label, blinded end-point evaluation trial. the patient population consists of patients on hemodialysis who have atrial fibrillation (af) and end-stage renal disease (esrd) .

this is a multicenter study in adult patients with af and esrd who are on hemodialysis and who have stroke risk factors making them candidates for oral anticoagulation. patients will be randomized to apixaban versus warfarin, and will be treated for up to 15 months.

Eligibility criteria:
inclusion criteria: * males and females, age at least 18 years, or the local age of consent, whichever is greater. * patients with af defined as af on ecg at enrollment or two or more reports of af from separate monitoring events at least 2 weeks apart (report of ecg, holter monitor, event monitor or implantable loop recorder). * cha2ds2-vasc score of ≥ 2. * end-stage renal disease treated with hemodialysis for ≥ 3 months. * considered by the treating physician(s) to be candidate for oral anticoagulation. * if of childbearing potential, be willing to avoid pregnancy during the study. exclusion criteria: * not considered by the treating physician(s) to be candidates for oral anticoagulation (for example, hemoglobin \< 8.5g/dl, history of intracranial hemorrhage, active bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic impairment, or anaphylactic reaction to apixaban) * moderate or severe mitral stenosis * conditions other than af that require anticoagulation such as mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism * need for aspirin at a dose \> 81 mg a day or need for p2y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor) * life expectancy \< 3 months * anticipated kidney transplant within the next 3 months * prisoners or others who are involuntarily incarcerated or detained * pregnant, breastfeeding, or considering pregnancy. * participation in a clinical trial of an experimental treatment within the past 30 days

Keywords: renal dialysis
barriers to physical activity in people with ms

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a chronic inflammatory disease leading to the demyelination of the central nervous system. promoting physical activity has gathered attention as an effective means to improve health-related quality of life and to mitigate symptoms such as fatigue and depressive symptoms in individuals suffering from ms. however, persons suffering from ms often experience difficulties in staying active. a comprehensive understanding of barriers to staying physical active for persons with ms in switzerland is currently lacking. given the importance of physical activity in the context of ms a detailed understanding of this matter would be key for future research and treatment. a key challenge when studying physical activity in the context of ms is to obtain objective and accurate measurements that are not prone to reporting bias. while accelerometer-based measurements hold promise in this regard they are not convenient for routine implementation in real-world environments. initial research has identified consumer-grade wearables such as fitbits as a promising alternative whereby focusing on the main outcome average step count. given the rich detail of activity patterns that can be derived from such devices, research has so far underutilized the available information that has the potential to provide more comprehensive insight into this matter. objectives: the present project aims to determine the common factors in real-life settings limiting physical activity in persons with ms and the impact of these barriers on physical activity. further, the present study aims to provide precedence for future research investigating physical activity in ms by examining the quality, reliability, internal consistency, and validity of pa metrics derived from the wide-spread consumer-grade activity tracker fitbit in comparison to an accelerometer.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * definite diagnosis of relapsing or progressive ms (i.e., confirmed by their physician) * persons with reduced walking ability but who are still able to walk independently with or without an assistive device (e.g., as expressed by an expanded disability status scale score between 3-6.5) * possess a personal computer, mobile phone or a tablet with bluetooth functionality, * be willing and able to perform study procedures, * be able to provide informed consent * be able to answer the questionnaires in german. exclusion criteria: * serious illnesses that preclude safe participation in physical activity * inability to follow study procedures * inability to complete questionnaires in german * inability to complete baseline questionnaires or activate the fitbit device will lead to the exclusion of the participant from the study

Keywords: multiple sclerosis physical acitivity digital mobility measurements real-life assessments
imiquimod 5% cream for the treatment of periocular basal cell carcinoma

Conditions: Carcinoma, Basal Cell

Summary: this study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

this is a prospective study including patients presenting in aggregate primary lesions affected by nodular bcc of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. all were submitted to a local treatment with imiquimod 5% cream (aldara ®), once daily, 5 days per week for 8-16 weeks (average). all subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.if positive biopsy (residue tumor) cases will managed with surgery.

Eligibility criteria:
inclusion criteria: * patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma). * patients with clinical counter indication for reconstructive surgery (high surgical risk). * patients who have refused a restorative surgery. (aesthetic reasons) * patients who have signed the free and informed consent. exclusion criteria: * patients who have a hypersensitivity reaction to the formula components. * children under 12 years of age. * pregnant and breastfeeding women. * patients whose injury was not confirmed by anatomical and pathological study. * individuals with previous autoimmune or inflammatory disease. * patients who have refused to sign the free and informed term of consent.

Keywords: immunomodulator carcinoma, basal cell
a phase ii study of cp-4055 as second line therapy in patients with advanced colorectal cancer

Conditions: Advanced Colorectal Cancer; Colorectal Cancer

Summary: patients with histologically or cytologically confirmed metastatic colorectal cancer (crc) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-fu) with or without bevacizumab, with or without other investigational medicinal products (imps), will receive cp-4055 200 mg/m2/day intravenously (iv) on day 1-5 every four weeks until complete response or disease worsening/progressing.

this is a multicentre clinical study conducted in the united kingdom. it is an open label study designed to investigate objective response rate (rr), the time to progression (ttp) and the duration of tumor response in patients with colorectal cancer when treated with cp-4055. the quantitative and qualitative toxicities of the treatment will also be assessed.

Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically confirmed metastatic crc who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-fu) with or without bevacizumab, with or without other investigational medicinal products (imps) 2. measurable disease according to response criteria in solid tumours (recist) 3. performance status 0 - 2 according to ecog (eastern cooperative oncology group) performance status 4. age 18 years or more 5. life expectancy \> 3 months 6. signed informed consent (ic) 7. women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to cp-4055 treatment. nursing patients are excluded. 8. male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last cp-4055 dose 9. adequate haematological and biological functions exclusion criteria: 1. known brain metastases 2. radiotherapy to more than 30 % of bone marrow 3. participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study 4. concomitant treatment with a non-permitted medication: * alternative drugs * high doses of vitamins 5. history of allergic reactions to ara-c or egg 6. any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection) 7. any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance 8. pregnancy, breastfeeding or absence of adequate contraception for both male and female fertile patients 9. known positive status for hiv and/or hepatitis b or c 10. drug and/or alcohol abuse 11. any reason why, in the investigator's opinion, the patient should not participate

Keywords: cp-4055 elacyt(tm) cancer colorectal cancer crc second line therapy
root resorption after maxillary expansion

Conditions: Maxillary Expansion

Summary: the aim of this study will to evaluate the root resorption after rme by hyrax and hybrid hyrax appliances by using of cone beam computed tomography .


Eligibility criteria:
inclusion criteria: 1. skeletal maxillary transvers deficiency 2. unilateral or bilateral posterior crossbite 3. negative buccal corridor 4. patient with good oral hygiene 5. patient with no previous orthodontic treatment 6. no systemic disease exclusion criteria: 1. craniofacial congenital anomalies 2. a history of periodontal disease 3. incomplete treatment records

Keywords: expanders
needle localization during prostate brachytherapy using power doppler ultrasound

Conditions: Prostate Cancer

Summary: this study involves patients who are scheduled for standard care brachytherapy of focal tumours within the prostate, which is normally performed under standard 2-dimensional (2d) ultrasound guidance. the purpose of this study is the acquire power doppler ultrasound while using a simple oscillator in physical contact with the end of a brachytherapy needle. the vibrations along the needle should be visible in the power doppler ultrasound, helping to visualize the needle position within the anatomy.


Eligibility criteria:
inclusion criteria: * male, aged 18 years or older * willing to provide written consent * pathologically confirmed prostate cancer on previous biopsy * suitable for and consenting to high-dose-rate brachytherapy for treatment as standard of care. exclusion criteria: * • previous radiotherapy to the prostate
gastro-oesophageal reflux and neurodisability (cerebral palsy) in children

Conditions: Cerebral Palsy; GORD; Pediatrics; GERD in Children; Quality of Life

Summary: this study assesses the content validity of the pgsq for parents/carer of children with cerebral palsy and gord, including features such as readability, face validity and acceptability for completion. this will be done via 6 interviews, with the pgsq being altered as identified as required. reliability (test-retest) of the adapted version of the pgsq being assessed with a sample of 20 parents/carers.

gastro-oesophageal reflux disease (gord) is a common condition, where acid from the stomach leaks up into the oesophagus (food pipe) causing highly unpleasant symptoms and sometimes needing hospital admission. children with cerebral palsy suffer from a poorly contracting food pipe (oesophageal dysmotility). as a result, gord is more problematic in these children and more common; of the 8000 children with cerebral palsy aged 5-16 in the uk, around half suffer from reflux disease. this is treated with medicines or surgery. there is not an accurate measure of their symptoms, though there is a suitable questionnaire in well children (the pgsq). national institute for health and clinical excellence (nice) have recommended research to assess the effectiveness of medicines to treat gord in these children (ng1 research recommendation). in the first phase, the investigators will ask 6 parents/carers their opinions about the pgsq using qualitative interviews, and alter the pgsq if needed; then in the second phase, ask 20 parents/carers about their child's symptoms to understand the reliability of the pgsq at two time points 2 weeks apart (test-retest). the investigators won't do any invasive tests on the children but will ask parents about their opinions of their children taking part in ph-impedance monitoring, which is used to assess severity of gord and may be useful in designing future studies.

Eligibility criteria:
inclusion criteria: * parents or carers of children with cerebral palsy (gmfcs level iii-v) with symptoms of gord or on treatment for presumed gord, aged between 2-16 years. exclusion criteria: * children whose parent/carer are not able to support their participation in the study in the opinion of the investigator (e.g. language/communication issue, health, burden).
a pilot study for pk/pd parameter of colchicine in chronic kidney disease patient.

Conditions: Chronic Kidney Disease

Summary: a pilot study for pk/pd parameter of colchicine in chronic kidney disease patient.


Eligibility criteria:
inclusion criteria: * from 18yrs to 80yrs , man and women * the patient who are taking colchicine * on screening, the patient shows that mdrd gfr \>= 10 ml/min and \<= 50 ml/min * the patient sign on the concent form exclusion criteria: * the patient have experience to take medication that have an effect on renal function * at least, the average level of two separate blood pressure ( 2min interval ) shows that sbp \ =160 mmhg and dbp \ =100 mmhg, or heart rate \ 90 beats/min * pregnancy or anticipate pregnancy with 6 month * hypersensitivity to colchicine * acute hepatitis or the level of ast or alt is over 2times of normal range or the level of bilirubin is over 2.0 mg/dl * serum albumin \ 5mg/dl * urinary retension, prostatic hyperplasia * the patient show gout attack on taking colchicine * the patient who have gastro-intestinal disease ( ex, crohn's disease, acute or chronic pancreatitis, ulcer )or who have the surgical history of gastrointestine. * the patient who should take atazanavir, amprenavir, apreptant, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil, cyclosporine, ranolazine * the patient who had taken part in the other study within 3months * the patient who had gotten blood transfusion * pregnant, breast feeding